Molecule
Sodium fluoride f-18 is a radioactive diagnostic agent indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity. It is available as injection for intravenous use. MedsAcross supplies Sodium fluoride f-18 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Sodium Fluoride F 18 Injection, USP is indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity. Sodium Fluoride F 18 Injection, USP is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.
Source: US FDA prescribing information
Fluoride F18 ion normally accumulates in the skeleton in an even fashion, with greater deposition in the axial skeleton (e.g. vertebrae and pelvis) than in the appendicular skeleton and greater deposition in the bones around joints than in the shafts of long bones.
Source: US FDA prescribing information
Sodium Fluoride F18 Injection emits radiation and must be handled with appropriate safety measures. Administer 300-450 MBq (8 to 12 mCi) as an intravenous injection in adults. Administer approximately
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Allergic Reactions: As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available. Cancer Risk: Sodium Fluoride F 18 Injection may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Source: US FDA prescribing information
No adverse reactions have been reported for Sodium Fluoride F 18 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems. However, the completeness of these sources is not known.
Source: US FDA prescribing information
The possibility of interactions of Sodium Fluoride F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.
Source: US FDA prescribing information
Store at 25°C (77°F) in a shielded container, excursions permitted to 15–30°C (59–86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Sodium fluoride f-18, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sodium fluoride f-18 200 mCi/mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium fluoride f-18 600 mCi/mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium fluoride f-18 91.5 mCi/mL injectionIntravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 24 February 1972 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Sodium fluoride f-18 and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Sodium fluoride f-18 on 24 February 1972, according to Drugs@FDA.
No listed presentation of Sodium fluoride f-18 is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.